Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focused on genetically defined rare diseases, announced its participation in key investor conferences. Management will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, and the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 3:20 p.m. ET. Live audio webcasts will be accessible on Fulcrum's Investor Relations page.

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences:

• Morgan Stanley 19th Annual Global Healthcare Conference
  Thursday, September 9, 2021 at 4:15 p.m. ET

• H.C. Wainwright 23rd Annual Global Investment Conference
  Monday, September 13, 2021 at 7:00 a.m. ET

• Cantor Virtual Global Healthcare Conference
  Tuesday, September 28, 2021 at 3:20 p.m. ET

Live audio webcasts will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 30 days.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia, into Phase 1 clinical development. 

Please visit www.fulcrumtx.com.

Contact:
Christi Waarich
Director, Investor Relations
and Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com

FAQ

What investor conferences is Fulcrum Therapeutics participating in September 2021?

Fulcrum Therapeutics will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and Cantor Virtual Global Healthcare Conference on September 28, 2021.

What is the focus of Fulcrum Therapeutics?

Fulcrum Therapeutics focuses on improving the lives of patients with genetically defined rare diseases through its proprietary product engine, FulcrumSeek.

What are the drug candidates under development by Fulcrum Therapeutics?

Fulcrum is developing losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for sickle cell disease and beta-thalassemia.

Where can I find the live webcasts for Fulcrum Therapeutics' investor presentations?

Live audio webcasts for Fulcrum Therapeutics' presentations will be available on their Investor Relations website.

How can I access archived replays of Fulcrum Therapeutics' presentations?

Archived replays of Fulcrum Therapeutics' presentations will be available on their website for 30 days after the events.